Bristol-Myers Squibb Stock News

Bristol-Myers Squibb's Q1 2025 results confirm that the stock has significant potential upside now. The company's Growth Portfolio showed healthy sales increase, while the non-GAAP EPS surprised positively, beating estimates by 20%. BMS upgraded its 2025 guidance a bit too, reducing expected revenue shrinkage to 4.1% and raising non-GAAP EPS expectations by 2.24%.

A 25% U.S. tariff on pharmaceutical imports would increase U.S. drug costs by nearly $51 billion annually, boosting U.S. prices by as much as 12.9% if passed on, a report commissioned by the industry's U.S. trade group and reviewed by Reuters shows.

Despite recent underperformance, Bristol-Myers' strong cash position, robust pipeline, and strategic acquisitions position it for future growth, making it an undervalued opportunity. BMY's growth portfolio is thriving, with significant YoY increases in key drugs, offsetting declines in its legacy products. BMY's consistent dividend growth and strong profitability make it an attractive income in...

Bristol-Myers Squibb Company (NYSE:BMY ) Q1 2025 Earnings Conference Call April 24, 2025 8:00 AM ET Company Participants Chuck Triano - SVP and Head of IR Chris Boerner - Board Chair and CEO David Elkins - CFO Adam Lenkowsky - CCO Samit Hirawat - CMO and Head of Global Drug Development Conference Call Participants Chris Schott - JPMorgan Mohit Bansal - Wells Fargo Luisa Hector - Berenberg Geoff...

Bristol-Myers Squibb Company is undervalued, trading 30% below its intrinsic value, with a low price-to-free-cash-flow ratio indicating a strong buying opportunity. In the first quarter, Bristol-Myers Squibb did beat expectations for revenue and earnings per share, but had to report declining sales. Management expects a revenue decline in 2025 due to legacy portfolio drops, but growth portfolio...

Bristol-Myers Squibb Company's Q1 2025 earnings show a 6% YoY revenue decline but improved EPS, with upgraded full-year guidance and a strong dividend yield of over 5%. BMY's growth portfolio is nearing 50% of revenues, but legacy assets and unmet peak revenue forecasts for new drugs raise concerns. Cobenfy's recent trial failure and underperformance of key assets like Sotyktu and Abecma contri...

Bristol Myers Squibb stock dropped Thursday, though the drugmaker beat first-quarter expectations and raised its outlook for the year.

Bristol Myers sees revenue decline in its legacy drug portfolio due to competition and Medicare headwinds.